Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1

International Journal of Oncology

Volumn 35, Issue 1, 2009, Pages 97-107

  Bauer, Lukas ^a   Venz, Simone ^a   Junker, Heike ^a   Brandt, Rowena ^a   Radons, JÜrgen ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Colo357; Interleukin 1; Nicotinamide phosporibosyltransferase; Pancreatic carcinoma; Prostaglandin H2 synthase 2; Proteomic analysis

Indexed keywords

BINDING PROTEIN; BUB3 PROTEIN; GLUTATHIONE REDUCTASE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1; LAMIN A; LAMIN C; LEUKOCYTE ELASTASE INHIBITOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROSTAGLANDIN SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SEPTIN; URIDINE TRIPHOSPHATE GLUCOSE 1 PHOSPHATE URIDYLYLTRANSFERASE;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CANCER SURVIVAL; CELL STIMULATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION;

ADENOCARCINOMA; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYTOKINES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PANCREATIC NEOPLASMS; PROTEOMICS; RECOMBINANT PROTEINS; RNA, MESSENGER; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS; UP-REGULATION;

EID: 67649419010     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000317     Document Type: Article

References (67)

1. Hart AR, Kennedy H and Harvey I: Pancreatic cancer: a review of the evidence on causation. Clin Gastroenterol Hepatol 6: 275-282, 2008.
2. Rosewicz S and Wiedenmann B: Pancreatic carcinoma. Lancet 349: 485-489, 1997.
3. Lowenfels AB and Maisonneuve P: Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20: 197-209, 2006.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
5. Le X, Shi Q, Wang B, et al: Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 20: 935-946, 2000.
6. Chua YJ and Cunningham D: Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol 23: 4532-4537, 2005.
7. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
8. Garcea G, Dennison AR, Steward WP and Berry DP: Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 5: 514-529, 2005.
9. Klapman J and Malafa MP: Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 15: 280-287, 2008.
10. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J and Whitcomb DC: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89: 442-446, 1997.
11. Angst E, Reber HA, Hines OJ and Eibl G: Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 144: 57-65, 2008.
12. Apte RN, Dotan S, Elkabets M, et al: The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25: 387-408, 2006.
13. Apte RN and Voronov E: Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 12: 277-290, 2002.
14. Apte RN, Krelin Y, Song X, et al: Effects of micro-environment and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 42: 751-759, 2006.
15. Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L and Evan GI: The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1α. Genes Dev 20: 2527-2538, 2006.
16. Radons J, Gabler S, Wesche H, Korherr C, Hofmeister R and Falk W: Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling. J Biol Chem 277: 16456-16463, 2002.
17. Wesche H, Korherr C, Kracht M, Falk W, Resch K and Martin MU: The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem 272: 7727-7731, 1997.
18. O'Neill LA and Greene C: Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol 63: 650-657, 1998.
19. Karin M: Nuclear factor-κB in cancer development and progression. Nature 441: 431-436, 2006.
20. Ummanni R, Junker H, Zimmermann U, et al: Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266: 171-185, 2008.
21. Röhl C, Armbrust E, Kolbe K, Lucius R, Maser E, Venz S and Gulden M: Activated microglia modulate astroglial enzymes involved in oxidative and inflammatory stress and increase the resistance of astrocytes to oxidative stress in vitro. Glia 56: 1114-1126, 2008.
22. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M and Kloppel G: A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442: 444-452, 2003.
23. Kalthoff H, Schmiegel W, Roeder C, et al: p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 8: 289-298, 1993.
24. He AR, Lindenberg AP and Marshall JL: Biologic therapies for advanced pancreatic cancer. Expert Rev Anticancer Ther 8: 1331-1338, 2008.
25. Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE and Mueller W: Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer - association with tumour cell proliferation. J Pathol 200: 16-22, 2003.
26. Yuan B, Xu Y, Woo JH, et al: Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12: 405-410, 2006.
27. Fu Z and Fenselau C: Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance. J Proteome Res 4: 1583-1591, 2005.
28. Khalil AA: Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 98: 201-213, 2007.
29. Craven RA, Hanrahan S, Totty N, et al: Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 6: 3880-3893, 2006.
30. Willis ND, Cox TR, Rahman-Casans SF, et al: Lamin A/C is a risk biomarker in colorectal cancer. PLoS ONE 3: e2988, 2008.
31. Molinaro RJ, Jha BK, Malathi K, Varambally S, Chinnaiyan AM and Silverman RH: Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Res 34: 6684-6695, 2006.
32. Ghosh D, Srivastava GP, Xu D, Schulz LC and Roberts RM: A link between SIN1 (MAPKAP1) and poly(rC) binding protein 2 (PCBP2) in counteracting environmental stress. Proc Natl Acad Sci USA 105: 11673-11678, 2008.
33. Silverman GA, Bird PI, Carrell RW, et al: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276: 33293-33296, 2001.
34. Padron-Barthe L, Courta J, Lepretre C, Nagbou A and Torriglia A: Leukocyte elastase inhibitor, the precursor of L-DNase II, inhibits apoptosis by interfering with caspase-8 activation. Biochim Biophys Acta 1783: 1755-1766, 2008.
35. Lee KA, Kang JW, Shim JH, et al: Protein profiling and identification of modulators regulated by human papillomavirus 16 E7 oncogene in HaCaT keratinocytes by proteomics. Gynecol Oncol 99: 142-152, 2005.
36. Brown LJ, Stoffel M, Moran SM, Fernald AA, Lehn DA, LeBeau MM and McDonald MJ: Structural organization and mapping of the human mitochondrial glycerol phosphate dehydrogenase-encoding gene and pseudogene. Gene 172: 309-312, 1996.
37. Mikuriya K, Kuramitsu Y, Ryozawa S, et al: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 30: 849-855, 2007.
38. Chowdhury SK, Gemin A and Singh G: High activity of mitochondrial glycerophosphate dehydrogenase and glycerophosphate-dependent ROS production in prostate cancer cell lines. Biochem Biophys Res Commun 333: 1139-1145, 2005.
39. Lin WY, Song CY and Pan TM: Proteomic analysis of Caco-2 cells treated with monacolin K. J Agric Food Chem 54: 6192-6200, 2006.
40. Moskovitz AH, Linford NJ, Brentnall TA, et al: Chromosomal instability in pancreatic ductal cells from patients with chronic pancreatitis and pancreatic adenocarcinoma. Genes Chromosomes Cancer 37: 201-206, 2003.
41. Chang HJ, Lee MR, Hong SH, et al: Identification of mitochondrial FoF1-ATP synthase involved in liver metastasis of colorectal cancer. Cancer Sci 98: 1184-1191, 2007.
42. Dowling P, Meleady P, Dowd A, Henry M, Glynn S and Clynes M: Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim Biophys Acta 1774: 93-101, 2007.
43. Kendal CE and Bryant-Greenwood GD: Pre-B-cell colonyenhancing factor (PBEF/Visfatin) gene expression is modulated by NF-κB and AP-1 in human amniotic epithelial cells. Placenta 28: 305-314, 2007.
44. Revollo JR, Grimm AA and Imai S: The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279: 50754-50763, 2004.
45. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H and Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178: 1748-1758, 2007.
46. Van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, Cregab SP and Pickering JG: Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 282: 10841-10845, 2007.
47. Folgueira MA, Carraro DM, Brentani H, et al: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11: 7434-7443, 2005.
48. Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruine AP, Arends J-W, Hoogenboom HR and Hufton SE: Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 101: 118-127, 2002.
49. Pollak N, Dolle C and Ziegler M: The power to reduce: pyridine nucleotides - small molecules with a multitude of functions. Biochem J 402: 205-218, 2007.
50. Olesen UH, Christensen MK, Bjorkling F, Jäättelä M, Jensen PB, Sehested M and Nielsen SJ: Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 367: 799-804, 2008.
51. Holen K, Saltz LB, Hollywood E, Burk K and Hanauske AR: The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26: 45-51, 2008.
52. Ravaud A, Cerny T, Terret C, et al: Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 41: 702-707, 2005.
53. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559, 1995.
54. Okami J, Yamamoto H, Fujiwara Y, et al: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 5: 2018-2024, 1999.
55. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215: 1-20, 2004.
56. Harper KA and Tyson-Capper AJ: Complexity of COX-2 gene regulation. Biochem Soc Trans 36: 543-545, 2008.
57. Shanmugam N, Reddy MA and Natarajan R: Distinct roles of heterogenous nuclear ribonuclear protein K and microrna-16 in cyclooxygenase-2 RNA stability induced by S100B, a ligand of the receptor for advanced glycation end products. J Biol Chem 283: 36221-36233, 2008.
58. Anderson P and Kedersha N: Stress granules: the Tao of RNA triage. Trends Biochem Sci 33: 141-150, 2008.
59. Yang VW, Shields JM, Hamilton SR, et al: Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 58: 1750-1753, 1998.
60. Fukuda R, Kelly B and Semenza GL: Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 63: 2330-2334, 2003.
61. Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524, 2005.
62. Gupta GP, Nguyen DX, Chiang AC, et al: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446: 765-770, 2007.
63. Okami J, Nakamori S, Hiraoka N, et al: Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor. Clin Exp Metastasis 20: 577-584, 2003.
64. Dragovich T, Burris H, III, Loehrer P, et al: Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 31: 157-162, 2008.
65. El-Rayes BF, Zalupski MM, Shields AF, et al: A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs 23: 583-590, 2005.
66. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080, 2005.
67. Adhami VM, Malik A, Zaman N, et al: Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 13: 1611-1619, 2007.